Updated:
Veracyte
Veracyte serves as an ally in the race against cancer, providing clinicians and patients with molecular tests that reveal key insights into tumor biology.
Veracyte
Veracyte serves as an ally in the race against cancer, providing clinicians and patients with molecular tests that reveal key insights into tumor biology.
General information
Firm type
Asset Manager
Location
Region
North America
Country
United States
City
South San Francisco
Corporate office
6000 Shoreline Court, Suite 300, South San Francisco, CA 94080, United States
Additional offices
San Diego, CA, United States · Austin, TX, United States · Haifa, Israel
Sector focus
Frequently asked questions
Which cancer types does Veracyte's commercial portfolio cover?
Veracyte's menu addresses thyroid, prostate, bladder, and breast cancer. The Afirma test assesses thyroid nodule malignancy risk, the Decipher Prostate and Bladder classifiers inform genitourinary treatment decisions, Prosigna provides a breast cancer recurrence score, and TrueMRD monitors muscle-invasive bladder cancer for residual disease. A lung cancer risk-assessment test, the Percepta Nasal Swab, remains in the pipeline.
Does Veracyte compete with liquid-biopsy or next-generation sequencing platforms?
Veracyte occupies a specific niche: tissue-based and limited liquid-based genomic classifiers that answer a discrete clinical question — such as whether to proceed to surgery, use chemotherapy, or escalate treatment — rather than broad panel sequencing. Its TrueMRD test does enter the ctDNA minimal-residual-disease monitoring space but is currently confined to muscle-invasive bladder cancer.
Where is Veracyte's testing performed and where does it sell?
The firm operates laboratory and office facilities in South San Francisco, San Diego, Austin, and Haifa, Israel. Its tests are primarily sold in the United States, with the Prosigna assay available as a CE-IVD test outside the U.S. Customer support lines are staffed during U.S. West Coast business hours.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: